Despite these limitations, >70 patents for P2RX7 antagonists have been filed in the last few years, including for the use of A438079 in depression, anxiety and bipolar disorders, triazole-based drugs for CNS disorders and P2RX7 antagonists in epithelial cancers (from GSK, Abbott and Cleveland University Hospitals, respectively (Park and Kim, 2016). This evidence concerns the gene P2RX7 and bipolar disorder.